PwC Greece’s Post

🌟"Redefining Value" in the Pharma Industry: Excited to have been part of the 𝟭𝘀𝘁 𝗦𝗙𝗘𝗘 𝗦𝘂𝗺𝗺𝗶𝘁🌟 Our Partner, Angelos Benos, Pharma & Healthcare Industry Lead at PwC Greece, took the stage yesterday at the 1st SFEE Summit, during an intriguing panel on “𝗘𝗻𝗵𝗮𝗻𝗰𝗶𝗻𝗴 𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗰𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲𝗻𝗲𝘀𝘀 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 & 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝗥&𝗗”💡Angelos contributed valuable insights and added depth to a discussion concerning investments of the Pharmaceutical sector in R&D and in particular Clinical Trials. Clinical trials represent a very significant Foreign Direct Investment pot that our country unfortunately has historically failed to claim its fair share and Angelos put forward certain policy initiatives that can help boost competitiveness and attract R&D investments by the Big-Pharma. #PwCGreece #SFEESummit2024 #HealthcareInnovation #GreekPharma

Let’s connect and create impactful solutions for a healthier future! EVA pharma RauCon Business Development See you in Dublin! 🌟 . . . . . . #EuroPLX #PharmaIndustry #BusinessDevelopment #Partnerships #Collaboration #Innovation #Healthcare #Biotech #Pharmaceuticals #LifeSciences #DrugDevelopment #HealthcareInnovation #ClinicalResearch #PharmaBusiness #HealthTech #GlobalHealth #MedicalResearch #PharmaPartnerships #BusinessGrowth #IndustryLeaders #HealthSolution

Next week's 18th National Pharmaceutical Congress, which will be held at the Mississauga Convention Centre on 11/06, offers the year's most essential discussions and the most knowledgeable faculty. The 22nd Canadian Healthcare Marketing Hall of Fame Awards luncheon is the centrepiece of this event. And as if that's not enough, NPC raises contributions for Camp Liberté, through Sandi's Fund. NPC is supported by the finest companies in the life sciences. You know the names. They are: -- 3H Communications -- Bayshore HealthCare -- BioScript Solutions -- Blue Charm Adherence -- Cencora -- Canadian Pharmaceutical Distribution Network -- Chronicle Companies -- Council for Continuing Pharmaceutical Education -- EMREACH Inc. -- Gibson Group Inc. -- Impres -- Inizio Engage -- IQVIA -- McKesson Canada -- Peak Pharma Solutions -- Shoppers Drug Mart Specialty Health Network -- The Pangaea Group -- Toc Toc Communications When you're putting out RFPs, please remember that these are the organizations that invest in valuable educational and networking events for life sciences managers and executives. That's why they are the Finest Companies in Healthcare. Register for the NPC here: https://lnkd.in/gBVFk876 #lifesciences #leadership #nationalpharmaceuticalcongress #npc2024

A new pan-European initiative aimed at creating a new less fragmented and more democratic ecosystem for clinical trials across the continent has been launched. Dubbed Research in Europe and Diversity Inclusion (READI), the new consortium, backed by a consortium of 73 continental healthcare entities, is led by the Servicio madrileño de salud (SERMAS) based out of the Spanish University Hospital of La Paz. It also has the backing of industry players ranging from biopharmaceutical giants such as Novo Nordisk, AbbVie and Roche, through to healthcare regulatory bodies such as the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) or Denmark’s Midtjyllands EU Kontor Forening (CDEU). It also comprises hospital sites and clinical research organisations (CROs) across the continent. Click here for the full article - https://lnkd.in/dd_P4hX2 #clinicaltrials #clinicaltrialdiversity #trialdiversity

Sanofi in Talks to Sell Majority Stake in Opella to Clayton Dubilier & Rice 💼💊 Sanofi (SASY.PA) is in discussions to sell a 50% controlling stake in its consumer healthcare unit, Opella, to U.S. private equity firm Clayton Dubilier & Rice (CD&R). The deal, estimated at €15 billion ($16.41 billion) 💶, aims to help Sanofi refocus on its core pharmaceutical business and new drug development. Opella, which employs over 11,000 people 👥 and owns popular brands like Doliprane 💊, has attracted bids from both CD&R and PAI Partners. The French finance ministry supports CD&R’s bid but requires commitments to keep Opella's headquarters and operations in France. #Sanofi #Opella #PharmaNews #PrivateEquity #HealthcareBusiness #PharmacyStudent #HealthcareTransformation

𝗥𝗲𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗰𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝗱: 𝗣𝗵𝗮𝗿𝗺𝗮 𝗗𝗲𝘂𝘁𝘀𝗰𝗵𝗹𝗮𝗻𝗱 𝘀𝘁𝗿𝗲𝗻𝗴𝘁𝗵𝗲𝗻𝘀 𝗘𝗮𝘀𝘁𝗲𝗿𝗻 𝗚𝗲𝗿𝗺𝗮𝗻𝘆 𝗮𝘀 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗛𝗼𝘁𝘀𝗽𝗼𝘁 💪🏻⚕️ Pharma Deutschland has completed its restructuring by founding the regional association for Eastern Germany. The association aims to establish eastern Germany as an important location for the healthcare industry. The regional structures consist of six associations, including the new Eastern Association, which covers Berlin, Brandenburg, Mecklenburg-Western Pomerania, Saxony, Saxony-Anhalt and Thuringia. Dr. Andreas Eberhorn from Dermapharm Holding SE heads this association. Eastern Germany is highlighted as a region with a strong #pharmaceutical industry, modern biotech clusters and leading #research institutions. The aim of the new association is to promote the exchange between industry, science and #politics in order to utilize the region's potential and make the pharmaceutical industry there fit for the future. Dorothee Brakmann, Managing Director of Pharma Deutschland, emphasizes that the regional associations are intended to strengthen the entire German pharmaceutical landscape and promote Germany as a pharmaceutical location as a whole. “We will work hard to further optimize the local ecosystem for pharmaceutical #innovation. Our aim is to establish eastern Germany as a hotspot for the #healthcare industry and increase its appeal beyond the state's borders.”, states Eberhorn. #pharmaindustrie #pharmaceuticalindustry #healthindustry #gesundheitssystem #pharma

With double of the US population and universal healthcare access, Europe represents the second largest healthcare market in the world.    Today we bid farewell to our “Think about Europe” series of posts; through which we described the challenges and commercial opportunity that Europe represents for US-based pharmaceutical and biotech companies looking to expand their footprint.    The topics we have discussed during the campaign are linked here and outlined below >> https://lnkd.in/dtbB3CAM   Our overall recommendations to manufacturers are: A) Think about Europe early in the clinical development process to maximise the European opportunity, we recommend it to be no later than in Phase II clinical trials.    B) Understand country level reimbursement processes and pricing potential to help decision-makers think more intelligently about resource allocation in the long term    c) Consider engaging with an experienced partner for European market access to mitigate the potential commercialisation challenges down the road.   The Cogentia team are well prepared to help you identify potential pitfalls for the European market and bring much needed treatments to patients across Europe.    #marketaccess #europe #HEOR  

📢 Last week, we launched the State of the Discovery Nation 2024 report, in partnership with the UK BioIndustry Association and the Association of the British Pharmaceutical Industry. Download here: https://hubs.li/Q02x3D3L0 The State of the Discovery Nation 2024 examines the sector’s challenges. It shows what is needed to secure a rich medicines pipeline and build on the UK’s global leadership in #LifeSciences. This includes: ---▶️ Creating strong partnerships with translational experts, who can take early-stage discoveries through to late-stage clinical development so #SMEs can de-risk assets for investment wherever they are in the UK ---▶️ Providing high-quality #laboratory facilities and incubator spaces for companies at all stages of maturity ---▶️ Make funds available, visible and accessible to support SMEs. Leverage private/public initiatives to co-develop pipelines of high-quality #FitToFund companies. In partnership with: Medicines Discovery Catapult | BioIndustry Association (BIA) | The Association of the British Pharmaceutical Industry (ABPI) #DrugDiscovery #SoDN2024 #Collaboration #SME

With double of the US population and universal healthcare access, Europe represents the second largest healthcare market in the world.    Today we bid farewell to our “Think about Europe” series of posts; through which we described the challenges and commercial opportunity that Europe represents for US-based pharmaceutical and biotech companies looking to expand their footprint >> find link to our articles here: https://lnkd.in/dtbB3CAM   The Cogentia team are well prepared to help you identify potential pitfalls for the European market and bring much needed treatments to patients across Europe.    #marketaccess #europe #HEOR

Germany's Pioneering DIGA Act Spurs Digital Health Innovation, With Limits While the RCTs required to meet DiGA’s standards are not as onerous as traditional pharmaceutical pivotal trials, they are still time-consuming, and the statue allows manufacturers to get an extendable one-year listing based on preliminary evidence, which enables them to generate revenue while they complete the more rigorous studies required for a permanent listing (see Figure 1 below). Germany’s high-profile DiGA legislation has successfully encouraged digital therapeutics innovation, according to two new studies, although critics say it still leaves room for improvement. The US company Enovis, which embraces digital therapeutics as a promising business, and its German start-up partner Orthopy Health GmbH are testing the DiGA waters in what Enovis considers to be an important ex-US market opportunity: https://bit.ly/4eWlwj6 #digitaltherapeutics #digitalhealth #medtechinnovation #digitalhealthinnovation #Germany #medtech